Early Initiation of Tumor Necrosis Factor Antagonist –Based Therapy for Patients With Crohn’s Disease Reduces Costs Compared With Late Initiation

Antagonists of tumor necrosis factor (TNF) are effective for induction and maintenance of remission of Crohn ’s disease (CD) and are generally prescribed when patients do not respond to conventional, less-costly medical therapies. Early initiation of anti-TNF therapy reduced rates of surgery and dose escalation due to loss of response. However, these drugs are expensive, so studies are needed on the cost effectiveness of early initiation. We aimed to determine the cost effectiveness of initiating treatment early in the disease course (within 2 years of CD diagnosis) vs later in the disease course (more than 2 years after diagnosis).
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research

Related Links:

Conclusions: The percentage of individuals sensitized to inhalants in CD and to inhalants and foods in UC, were higher than corresponding results in BD. However, whereas allergen positive reactions in CD were comparable to those in BD, they were reduced in UC because of the few UC reactions to food allergens. This contrasts previous data and the study also points to sensitization to inhalants as a potential factor in the complex pathogenesis of IBD. PMID: 31524013 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
CONCLUSION: A number of studies have showed an association between PD and IBD. Both diseases share genetic and environmental etiological factors. The precise role of intestinal bacteria remains vague. The periodontal microbiota that might be involved in the association of these diseases are Fusobacterium nucleatum, Campylobacter rectus and Campylobacter concisus. Fungal and viral microbiota dysbiosis should also be evaluated as common pathogenic pathways in IBD and periodontal disease. PMID: 31522142 [PubMed - in process]
Source: Journal of the International Academy of Periodontology - Category: Dentistry Tags: J Int Acad Periodontol Source Type: research
Is there an increased risk of developing de novo inflammatory bowel disease while under treatment with anti-TNF-alpha for other chronic inflammatory or immune-mediated diseases?Alimentary Pharmacology &Therapeutics
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news
Eun Ju Jeong Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), are autoimmune diseases characterized by chronic inflammation within the gastrointestinal tract. Debromohymenialdisine is an active pyrrole alkaloid that is well known to serve as a stable and effective inhibitor of Chk2. In the present study, we attempted to investigate the anti-inflammatory properties of (10Z)-debromohymenialdisine (1) isolated from marine sponge Stylissa species using an intestinal in vitro model with a transwell co-culture system. The treatment with 1 attenuated th...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
CONCLUSIONS: The concordance between PT and IGRA is affected in patients with EIMI, and to a greater extent to patients with the inflammatory bowel disease, with the corticotherapy, with the BCG vaccination, or in the ones from endemic countries. PMID: 31523944 [PubMed - as supplied by publisher]
Source: Revista Espanola de Quimioterapia - Category: Drugs & Pharmacology Authors: Tags: Rev Esp Quimioter Source Type: research
Conditions:   Arthritis, Rheumatoid (RA);   Axial Spondyloarthritis (axSpA);   Arthritis, Psoriatic (PsA);   Crohn's Disease (CD);   Colitis, Ulcerative (UC) Intervention:   Drug: Adalimumab Sponsor:   Biogen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Interventions:   Diagnostic Test: blood biomarkers;   Diagnostic Test: stool biomarkers;   Diagnostic Test: MRI imaging Sponsors:   Children's Hospital Medical Center, Cincinnati;   The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Arthritis, Rheumatoid (RA);   Axial Spondyloarthritis (axSpA);   Arthritis, Psoriatic (PsA);   Crohn's Disease (CD);   Colitis, Ulcerative (UC) Intervention:   Drug: Adalimumab Sponsor:   Biogen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Interventions:   Diagnostic Test: blood biomarkers;   Diagnostic Test: stool biomarkers;   Diagnostic Test: MRI imaging Sponsors:   Children's Hospital Medical Center, Cincinnati;   The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Arthritis, Rheumatoid (RA);   Axial Spondyloarthritis (axSpA);   Arthritis, Psoriatic (PsA);   Crohn's Disease (CD);   Colitis, Ulcerative (UC) Intervention:   Drug: Adalimumab Sponsor:   Biogen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Crohn's Disease | Gastroenterology | Study